Division of Nephrology, Stanford University School of Medicine, Palo Alto, CA.
Division of Nephrology, Stanford University School of Medicine, Palo Alto, CA.
Am Heart J. 2020 Mar;221:67-73. doi: 10.1016/j.ahj.2019.12.013. Epub 2019 Dec 27.
When prescribing diuretics in the postcardiac surgical intensive care unit (ICU), clinicians may use central venous pressure (CVP) to assess volume status and the risk of acute kidney injury (AKI). In this study, we examined how the risk of diuretic-associated AKI varied with CVP in patients undergoing cardiac surgery.
We used the Medical Information Mart for Intensive Care database to study adults admitted to the postcardiac surgical ICU at an urban, academic medical center between 2001 and 2012. We examined the odds of AKI per 1-mm Hg increase in CVP among patients receiving intravenous loop diuretics using multivariable adjusted logistic regression. We examined the risk of AKI among patients with diuretic use (vs nonuse) across tertiles of CVP using inverse probability treatment weighting.
Among 4,164 patients receiving intravenous loop diuretics, the adjusted odds of subsequent AKI were 1.11 (95% CI 1.08-1.13) times higher per mm Hg increase in mean CVP. This association was log-linear across the entire range of CVPs observed. In the analysis of diuretic use (n = 5,396), the adjusted risk ratio for AKI with diuretic use (vs nonuse) was 1.33 (95% CI 1.21-1.47) and did not materially differ across tertile of CVP.
Higher rather than lower CVP is an independent marker of AKI risk. The risk of AKI associated with diuretic use may not be influenced by CVP. Novel methods of assessing volume status and AKI risk are needed to guide patient selection for diuretic therapy.
在心脏手术后的重症监护病房(ICU)中开具利尿剂时,临床医生可能会使用中心静脉压(CVP)来评估容量状态和急性肾损伤(AKI)的风险。在这项研究中,我们研究了在接受心脏手术的患者中,CVP 与利尿剂相关的 AKI 风险的变化。
我们使用医疗信息集市重症监护数据库研究了 2001 年至 2012 年间在城市学术医疗中心接受心脏手术后 ICU 治疗的成年人。我们使用多变量调整逻辑回归,检查接受静脉滴注袢利尿剂的患者中 CVP 每增加 1mmHg 时 AKI 的发生几率。我们使用逆概率治疗加权(inverse probability treatment weighting)检查 CVP 三分位数中利尿剂使用(vs 非使用)患者的 AKI 风险。
在 4164 名接受静脉滴注袢利尿剂的患者中,平均 CVP 每增加 1mmHg,随后 AKI 的调整后几率增加 1.11(95%CI 1.08-1.13)倍。在整个观察到的 CVP 范围内,这种关联呈对数线性。在利尿剂使用的分析中(n=5396),利尿剂使用(vs 非使用)的 AKI 调整风险比为 1.33(95%CI 1.21-1.47),且与 CVP 三分位数没有明显差异。
较高而不是较低的 CVP 是 AKI 风险的独立标志物。与利尿剂使用相关的 AKI 风险可能不受 CVP 影响。需要新的方法来评估容量状态和 AKI 风险,以指导利尿剂治疗的患者选择。